Germ Cell Tumors Clinical Trials

A listing of Germ Cell Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1052 clinical trials
None
Study of Genes and Environment in Patients With Cancer in East Anglia Trent or West Midlands Regions of the United Kingdom

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This study is looking at genetic susceptibility to cancer and interactions between genes and the environment in patients with cancer …

cancer
  • 64 views
  • 07 Nov, 2020
  • 1 location
None
Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors

Prospective, open-label, dose-ranging, uncontrolled phase I study with PM01183 in combination with irinotecan to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183 in combination with irinotecan in patients with selected advanced solid tumors.

direct bilirubin
cytotoxic chemotherapy
sarcoma
neuroendocrine tumor
cancer of the ovary
  • 0 views
  • 10 Oct, 2021
  • 3 locations
None
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.

primary cancer
melanoma skin
carcinoma
measurable disease
squamous cell carcinoma
  • 101 views
  • 07 Aug, 2021
  • 35 locations
None
Genomic Investigation of Unusual Responders

Studies have shown that tumors from the same patient may respond very differently to the same therapeutic agents. This study aims to investigate the genetic basis of tumors that respond abnormally well or poorly to therapeutic agents in an effort to understand the fundamental genetic basis of this response. The …

therapeutic agents
  • 6 views
  • 27 Jan, 2021
  • 1 location
None
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

This is a phase I/Ib, open label study. The escalation portion will characterize the safety and tolerability of DKY709 and DKY709 in combination with PDR001 in subjects with NSCLC or melanoma who have received prior anti-PD-1/PD-L1 therapy, or subjects with NPC. After the determination of the MTD/RD for a particular …

core needle biopsy
metastasis
programmed cell death 1 ligand 1
measurable disease
solid tumour
  • 113 views
  • 29 Nov, 2021
  • 9 locations
None
Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies

This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.

esophagus cancer
gliosarcoma
blood urea nitrogen
measurable disease
chemoradiotherapy
  • 11 views
  • 15 Feb, 2021
  • 1 location
None
MGC018 With or Without MGA012 in Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of MGC018 administered alone and in combination with MGA012 in patients with advanced solid tumors.

pd-l1
mgc018
chemotherapy regimen
solid tumour
measurable disease
  • 12 views
  • 29 Oct, 2021
  • 20 locations
None
Phase 2 CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in solid tumors

cab-axl-adc
measurable disease
solid tumour
renal function
kidney function tests
  • 55 views
  • 21 Sep, 2021
  • 16 locations
None
Immune Related-adverse Events in Patients Receiving Immune Checkpoint Inhibitors

The recent introduction of anti-PD-1 (nivolumab and pembrolizumab) and anti- PD-L1 (atezolizumab, durvalumab, avelumab) immune checkpoint inhibitors revolutionized oncological guidelines. Durable responses and prolongation of survival with these agents come at the price of the development of immune related adverse events (irAEs). Innovative tools are required in order to manage …

primary cancer
programmed cell death 1 ligand 1
carcinoma
histological diagnosis
atezolizumab
  • 3 views
  • 23 Jan, 2021
  • 2 locations
None
Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

ONCR-177-101 is a phase 1, open-label, multi-center, dose escalation and expansion study of ONCR-177, an oncolytic Herpes Simplex Virus for intratumoral injection, alone and in combination with PD-1 blockade in adult subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors or with Liver Metastases of Solid Tumors. …

primary cancer
solid neoplasm
chemotherapy regimen
solid tumour
measurable disease
  • 0 views
  • 24 May, 2021
  • 9 locations